Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
But with Brukinsa and degraders looming, will fixed dosing make the difference?
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
